Is Peter Attia a real doctor?
Peter Attia (born 19 March 1973) is a Canadian-American physician of Coptic Egyptian descent known for his medical practice that focuses on the science of longevity. He is also the first person to make the round-trip swim from Maui and Lanai.
Did Peter Attia move to Austin?
Rogan's unofficial Austin-based squad now includes “The Drive” podcast host Peter Attia who moved with his family in 2021; “Kill Tony” podcaster Tony Hinchcliffe who moved in late 2020; “American Optimist” podcaster Joe Lonsdale who moved in November 2020; and comedian couple and “Your Mom's House” podcasters Tom ...
Does Peter Attia have a book?
Outlive by Peter Attia, MD: 9780593236598 | PenguinRandomHouse.com: Books.
Where is Peter Attia from?
Toronto, CanadaPeter Attia / Place of birth
Did Tom Segura move to Austin TX?
The couple's new home is just down the river from the 10,980-square-foot mansion in Austin that podcaster and comedian Joe Rogan purchased in 2020 for $14.4 million. Segura, 42, and Pazsitzky, 45, cohost the popular “Your Mom's House” podcast, which has 1.1 million subscribers on YouTube.
Why are people moving from Silicon Valley to Austin?
An impossible housing market, high tax rates, and strict regulations have made it challenging to live, work, and do business in Silicon Valley. Many CEOs are opting to leave California in search of lower real estate prices, better tax laws, and fewer restrictions.
How often does Peter Attia fast?
However, for 2020 he does a 3 day fast once per month, without the strict keto diet either side. He made the switch for 2 key reasons: 7-day fasts are intrusive on life. During the 7-day fast, it was typically day 2 where he saw a big shift in his glucose/ketone levels.
Why did Peter Attia leave surgery?
A change of heart – tired of the notion that doctors did little to keep patients healthy – led him to leave medicine; Dr. Attia joined renowned consulting firm McKinsey & Company where he worked on healthcare and financial system problems.
Where did Peter Attia go to medical school?
Peter Attia, a physician focusing on the applied science of longevity. Peter earned his M.D. from Stanford University and holds a B.Sc. in mechanical engineering and applied mathematics.
When did Peter Attia learn to swim?
Dr. Peter Attia was the guest, and he started with talking about some of his experiences as an open water swimming. The guy didn't even start swimming until age 31, and went on to do marathon swims! Amazing and inspiring.
Who is David Nutt?
David Nutt is a psychiatrist and a neuroscientist at Downing College, Cambridge. His research focuses on illicit drugs—their harm, classification, and potential for therapeutic use in psychiatry. In this episode, David discusses his framework for assessing the potential harm caused by common recreational drugs and explains how they are regulated, which is oftentimes misaligned with actual risk. He describes in detail the neurobiology, mechanisms of action, and addiction potential of alcohol, opiates, cocaine, and methamphetamine and contrasts those with psychedelics, which have been given a similar regulatory classification despite their relatively low risk of harm and their numerous potential therapeutic uses. Additionally, David explains the promise of psychedelics like ketamine, MDMA, and psilocybin for treating drug addiction and depression and discusses how political pressures have created roadblocks to future necessary research. We discuss: David’s early interest in the brain and experience in psychiatry [2:45]; David’s brief work on government drug policy in the UK [10:15]; A scale for rating the relative harm of certain drugs [13:45]; The contrast in regulation between cannabis vs. alcohol and why research on potential benefits of cannabis is lacking [19:15]; The opiate crisis and rise of fentanyl: the cause and potential solution [25:00]; The science of addiction and the potential use of psychedelics for treating drug addiction [35:00]; Cocaine: mechanisms of action and risks [41:45]; Methamphetamine and crystal meth: mechanisms of action and neurotoxicity [48:15]; How psychedelics came to be classified as schedule I drugs despite their numerous therapeutic uses [52:45]; The history of MDMA and the bad science and political forces leading to its demonization [1:08:45]; History of ketamine, medical use of esketamine, and the waning effects of psychedelics with increasing usage [1:13:30]; Psilocybin for depression: David’s promising research and the roadblocks to more robust experiments [1:20:15]; More. Learn more: https://peterattiamd.com/ Show notes page for this episode: https://peterattiamd.com/davidnutt Subscribe to receive exclusive subscriber-only content: https://peterattiamd.com/subscribe/ Sign up to receive Peter's email newsletter: https://peterattiamd.com/newsletter/ Connect with Peter on Facebook | Twitter | Instagram.
Who is Allan Sniderman?
Allan Sniderman is a highly acclaimed Professor of Cardiology and Medicine at McGill University and a foremost expert in cardiovascular disease (CVD). In this episode, Allan explains the many risk factors used to predict atherosclerosis, including triglycerides, cholesterol, and lipoproteins, and he makes the case for apoB as a superior metric that is currently being underutilized. Allan expresses his frustration with the current scientific climate and its emphasis on consensus and unanimity over encouraging multiple viewpoints, thus holding back the advancement of metrics like apoB for assessing CVD risk, treatment, and prevention strategies. Finally, Allan illuminates his research that led to his 30-year causal model of risk and explains the potentially life-saving advantages of early intervention for the prevention of future disease. We discuss: Problems with the current 10-year risk assessment of cardiovascular disease (CVD) and the implications for prevention [4:30]; A primer on cholesterol, apoB, and plasma lipoproteins [16:30]; Pathophysiology of CVD and the impact of particle cholesterol concentration vs. number of particles [23:45]; Limitations of standard blood panels [29:00]; Remnant type III hyperlipoproteinemia—high cholesterol, low Apo B, high triglyceride [32:15]; Using apoB to estimate risk of CVD [37:30]; How Mendelian randomization is bolstering the case for ApoB as the superior metric for risk prediction [40:45]; Hypertension and CVD risk [49:15]; Factors influencing the decision to begin preventative intervention for CVD [58:30]; Using the coronary artery calcium (CAC) score as a predictive tool [1:03:15]; The challenge of motivating individuals to take early interventions [1:12:30]; How medical advancement is hindered by the lack of critical thinking once a “consensus” is reached [1:15:15]; PSK9 inhibitors and familial hypercholesterolemia: two examples of complex topics with differing interpretations of the science [1:20:45]; Defining risk and uncertainty in the guidelines [1:26:00]; Making clinical decisions in the face of uncertainty [1:31:00]; How the emphasis on consensus and unanimity has become a crucial weakness for science and medicine [1:35:45]; Factors holding back the advancement of apoB for assessing CVD risk, treatment, and prevention strategies [1:41:45]; Advantages of a 30-year risk assessment and early intervention [1:50:30]; More. Learn more: https://peterattiamd.com/ Show notes page for this episode: https://peterattiamd.com/AllanSniderman Subscribe to receive exclusive subscriber-only content: https://peterattiamd.com/subscribe/ Sign up to receive Peter's email newsletter: https://peterattiamd.com/newsletter/ Connect with Peter on Facebook | Twitter | Instagram.
